Published online Jul 6, 2021. doi: 10.12998/wjcc.v9.i19.5280
Peer-review started: February 9, 2021
First decision: February 28, 2021
Revised: March 11, 2021
Accepted: April 25, 2021
Article in press: April 25, 2021
Published online: July 6, 2021
Processing time: 134 Days and 21.3 Hours
Glycogen storage disease type Ib (GSD-Ib) is a glycogen metabolism disorder that leads to the manifestations of inflammatory bowel disease (IBD), especially Crohn’s disease (CD)-like colitis. Although biological agents are effective for treating CD, their application in the treatment of GSD-Ib with CD-like colitis has been rarely reported.
A 13-year-old Han male was diagnosed with GSD-Ib with CD. The patient was treated with granulocyte colony-stimulating factor. When he had symptoms of CD-like colitis, he was continuously pumped with enteral nutrition and administered oral mesalazine for 2 wk; however, the symptoms did not improve significantly. Hence, infliximab (IFX) was administered. Hitherto, the patient has been followed up for 1 year, and no clinical manifestations have been observed. After 6 mo of treatment (fifth IFX treatment), the disease activity index and all inflammatory indexes decreased, and a review of the colonoscopy data showed that the ulcers appeared smooth.
In this study, the patient was successfully treated with IFX. In cases of GSD-Ib, IBD should be highly considered.
Core Tip: Conventional treatment cannot alleviate symptoms of intestinal inflammation in glycogen storage disease type Ib (GSD-Ib). Although biological agents are effective for treating Crohn’s disease (CD), their application in the treatment of GSD-Ib with CD has been rarely reported. Infliximab was selected for this patient, and the intestinal symptoms were successfully alleviated. For cases with poor outcome using the granulocyte colony-stimulating factor treatment, infliximab can be used for therapy.